154 related articles for article (PubMed ID: 10625928)
1. Telomere-interactive agents affect proliferation rates and induce chromosomal destabilization in sea urchin embryos.
Izbicka E; Nishioka D; Marcell V; Raymond E; Davidson KK; Lawrence RA; Wheelhouse RT; Hurley LH; Wu RS; Von Hoff DD
Anticancer Drug Des; 1999 Aug; 14(4):355-65. PubMed ID: 10625928
[TBL] [Abstract][Full Text] [Related]
2. Effect of telomere and telomerase interactive agents on human tumor and normal cell lines.
Rha SY; Izbicka E; Lawrence R; Davidson K; Sun D; Moyer MP; Roodman GD; Hurley L; Von Hoff D
Clin Cancer Res; 2000 Mar; 6(3):987-93. PubMed ID: 10741725
[TBL] [Abstract][Full Text] [Related]
3. The different biological effects of telomestatin and TMPyP4 can be attributed to their selectivity for interaction with intramolecular or intermolecular G-quadruplex structures.
Kim MY; Gleason-Guzman M; Izbicka E; Nishioka D; Hurley LH
Cancer Res; 2003 Jun; 63(12):3247-56. PubMed ID: 12810655
[TBL] [Abstract][Full Text] [Related]
4. Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells.
Izbicka E; Wheelhouse RT; Raymond E; Davidson KK; Lawrence RA; Sun D; Windle BE; Hurley LH; Von Hoff DD
Cancer Res; 1999 Feb; 59(3):639-44. PubMed ID: 9973212
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effects of telomerase inhibitor TMPyP4 in osteosarcoma cell lines.
Fujimori J; Matsuo T; Shimose S; Kubo T; Ishikawa M; Yasunaga Y; Ochi M
J Orthop Res; 2011 Nov; 29(11):1707-11. PubMed ID: 21590716
[TBL] [Abstract][Full Text] [Related]
6. Alterations in DNA repair and telomere maintenance mechanism affect response to porphyrins in yeast.
Izbicka E; Barnes LD; Robinson AK; Davidson KK; Lawrence RA; Hannibal GT
Anticancer Res; 2001; 21(3B):1899-903. PubMed ID: 11497275
[TBL] [Abstract][Full Text] [Related]
7. A hexameric phosphorothioate oligonucleotide telomerase inhibitor arrests growth of Burkitt's lymphoma cells in vitro and in vivo.
Mata JE; Joshi SS; Palen B; Pirruccello SJ; Jackson JD; Elias N; Page TJ; Medlin KL; Iversen PL
Toxicol Appl Pharmacol; 1997 May; 144(1):189-97. PubMed ID: 9169084
[TBL] [Abstract][Full Text] [Related]
8. Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells.
Chen Z; Koeneman KS; Corey DR
Cancer Res; 2003 Sep; 63(18):5917-25. PubMed ID: 14522918
[TBL] [Abstract][Full Text] [Related]
9. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects.
Kelland LR
Eur J Cancer; 2005 May; 41(7):971-9. PubMed ID: 15862745
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach.
Mo Y; Gan Y; Song S; Johnston J; Xiao X; Wientjes MG; Au JL
Cancer Res; 2003 Feb; 63(3):579-85. PubMed ID: 12566299
[TBL] [Abstract][Full Text] [Related]
11. Telomerase inhibition, telomere shortening, cell growth suppression and induction of apoptosis by telomestatin in childhood neuroblastoma cells.
Binz N; Shalaby T; Rivera P; Shin-ya K; Grotzer MA
Eur J Cancer; 2005 Dec; 41(18):2873-81. PubMed ID: 16253503
[TBL] [Abstract][Full Text] [Related]
12. Antisense oligonucleotide-mediated inhibition of hTERT, but not hTERC, induces rapid cell growth decline and apoptosis in the absence of telomere shortening in human prostate cancer cells.
Folini M; Brambilla C; Villa R; Gandellini P; Vignati S; Paduano F; Daidone MG; Zaffaroni N
Eur J Cancer; 2005 Mar; 41(4):624-34. PubMed ID: 15737568
[TBL] [Abstract][Full Text] [Related]
13. Telomerase inhibition is a specific early event in salvicine-treated human lung adenocarcinoma A549 cells.
Liu WJ; Zhang YW; Shen Y; Jiang JF; Miao ZH; Ding J
Biochem Biophys Res Commun; 2004 Oct; 323(2):660-7. PubMed ID: 15369801
[TBL] [Abstract][Full Text] [Related]
14. The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo.
Grand CL; Han H; Muñoz RM; Weitman S; Von Hoff DD; Hurley LH; Bearss DJ
Mol Cancer Ther; 2002 Jun; 1(8):565-73. PubMed ID: 12479216
[TBL] [Abstract][Full Text] [Related]
15. Telomerase inhibitors.
Rowley PT; Tabler M
Anticancer Res; 2000; 20(6B):4419-29. PubMed ID: 11205282
[TBL] [Abstract][Full Text] [Related]
16. [Azidothymidine, blocking telomerase functioning, shortens telomeric repeats in transformed human cells].
Egorov EE; Akhmalisheva AKh; Smirnova IuB; Shinkarev DB; Chernov DN; Zelenin AV; Kraevskiĭ AA
Genetika; 1997 Oct; 33(10):1444-6. PubMed ID: 9445812
[TBL] [Abstract][Full Text] [Related]
17. [The effect of telomerase inhibitors on oral squamous carcinoma cells].
Yang Z; Chen W; Zhang Q
Hua Xi Kou Qiang Yi Xue Za Zhi; 2003 Jun; 21(3):231-4. PubMed ID: 12898773
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of G-quadruplex-interactive agent TMPyP4 in K562 leukemic cells.
Mikami-Terao Y; Akiyama M; Yuza Y; Yanagisawa T; Yamada O; Yamada H
Cancer Lett; 2008 Mar; 261(2):226-34. PubMed ID: 18096315
[TBL] [Abstract][Full Text] [Related]
19. Irreversible telomere shortening by 3'-azido-2',3'-dideoxythymidine (AZT) treatment.
Gomez DE; Tejera AM; Olivero OA
Biochem Biophys Res Commun; 1998 May; 246(1):107-10. PubMed ID: 9600076
[TBL] [Abstract][Full Text] [Related]
20. Oligonucleotide N3'-->P5' phosphoramidates as efficient telomerase inhibitors.
Herbert BS; Pongracz K; Shay JW; Gryaznov SM
Oncogene; 2002 Jan; 21(4):638-42. PubMed ID: 11850790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
